Polaris Group (6550.TW) Stock
Polaris Group, together with its subsidiaries, offers biotechnology, drug testing, and contract development and manufacturing services. The company engages in the research, development, manufacture and sale of new drugs.
Valuation
Financials & Margins
Valuation & Return Ratios
Peer Comparison
About Polaris Group
Polaris Group, together with its subsidiaries, offers biotechnology, drug testing, and contract development and manufacturing services. The company engages in the research, development, manufacture and sale of new drugs. It develops ADI-PEG 20 for the treatment of various cancer indications, as well as provides healthcare consulting, staffing, and MDS solutions. The company was incorporated in 2006 and is based in Grand Cayman, Grand Cayman.
Polaris Group is led by CEO Samuel Chen, employs 83,293 people, headquartered in Grand Cayman, KY, publicly traded since 2016.
over the past 52 weeks the stock has ranged between $15.75 and $72.09, and currently trades 77.7% below its 52-week high.
Official website: www.polaris-group.com
Polaris Group (6550.TW) — frequently asked questions
What is Polaris Group (6550.TW) stock price today?
Polaris Group (6550.TW) is currently trading at $16.10, down 1.53% today.
Related — Stocks
Popular Stocks
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.